It has also been used off-label and studied in the treatment of coagulopathy in trauma patients [4–7]. The use of rFVIIa for non-approved indications has been formally evaluated in clinical trials (including two randomized controlled trials in trauma) [8–10], and shown to be of no survival benefit ; and with clear evidence of harm, particularly in the elderly . Despite the lack of supporting evidence, transfusion guidelines in either military or civilian https://www.selleckchem.com/products/qnz-evp4593.html settings currently suggest the use of rFVIIa as a last resort for the management of refractory coagulopathy in trauma [13–16]. However, when the drug is used in these settings of massive Ruboxistaurin hemorrhage, its efficacy as a pro-hemostatic agent may vary under
different physiologic conditions, particularly in acidosis [17, 18]. In metabolic acidosis, when pH levels are under 7.2, the activity of rFVIIa is significantly stunted. In fact, GW786034 order an investigation
conducted by Meng et al. indicated that the activity of rFVIIa decreased by over 90% at a pH level of 7.0 . Furthermore, high expenditures are associated with off-label use of rFVIIa . Therefore, the use of rFVIIa as a last resort when there is severe metabolic acidosis during significant hemorrhage in trauma might be considered inappropriate. We reviewed a cohort of massively transfused trauma patients to whom rFVIIa was administered to evaluate its utility as a last resort for the management of traumatic coagulopathy. The objective of this study was to identify critical degrees of acidosis and associated factors at which the use of rFVIIa might be considered of no utility. Methods This study was conducted at Tory Regional Trauma Centre of Sunnybrook Health Sciences Centre (SHSC), a large Canadian Level I adult trauma Mirabegron facility. The study protocol was reviewed and approved by the Hospital Research Ethics Board. Study cohort Patient information was obtained from the Blood Bank information system (HCLL, Mediware, N.Y.) at SHSC and the computerized Trauma Registry. The cohort was comprised of patients admitted from January 1, 2000 to November 30, 2006, with
the following inclusion criteria: (1) having been massively transfused, defined as having received 8 or more units of red blood cells (RBCs) within the first 12 hours (h) of admission (analogous to established criterion in recent randomized control trials on rFVIIa in trauma) [8, 9]; (2) having received rFVIIa; (3) having recorded pH values; (4) and having recorded times during which dosages of rFVIIa were administered (from admission to administration). Last resort use of rFVIIa was defined based on Receiver Operating Characteristics (ROC) curve analysis for survival. The ROC curve was determined to define a specific pH cutoff at which the test could appropriately discriminate the two groups based on the highest sensitivity for identifying potential survivors.